Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms
The purpose of this study is to determine if telmisartan is effective in slowing the progression of abdominal aortic aneurysms and reducing circulating concentrations of Abdominal Aortic Aneurysms (AAA) biomarkers.
Stanford is now accepting new patients for this trial.
- drug : Placebo
- drug : Telmisartan
Phase: Phase 4
Ages Eligible For Study:
- 50-85 years of age and able to provide written informed consent - AAA measuring a maximum diameter of 3.5-4.9 cm on CTA or ultrasound - Stable medication regime for the last six months - No current indication for AAA repair according to the treating physician or expectation that this will be revised within the next year - High likelihood of compliance with treatment over 24 months